These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25050065)

  • 21. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
    Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
    N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
    Liu H; Hu Y; Li FF; Liu BL; Su XF; Ma JH
    Diabetes Ther; 2016 Dec; 7(4):743-753. PubMed ID: 27734321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
    Cook W; Bryzinski B; Slater J; Frederich R; Allen E
    Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
    Gilbert MP; Pratley RE
    Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P
    Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Saxagliptin: a new drug for the treatment of type 2 diabetes.
    Thareja S; Aggarwal S; Malla P; Haksar D; Bhardwaj TR; Kumar M
    Mini Rev Med Chem; 2010 Jul; 10(8):759-65. PubMed ID: 20402634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study.
    Cobretti MR; Bowman B; Grabarczyk T; Potter E
    Pharmacotherapy; 2018 Mar; 38(3):334-340. PubMed ID: 29364549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.
    Li CJ; Liu XJ; Bai L; Yu Q; Zhang QM; Yu P; Yu DM
    Diabetol Metab Syndr; 2014; 6():69. PubMed ID: 24917890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis.
    Men P; Li XT; Tang HL; Zhai SD
    PLoS One; 2018; 13(5):e0197321. PubMed ID: 29787616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus.
    Kaku K; Kisanuki K; Shibata M; Oohira T
    Drug Saf; 2019 Nov; 42(11):1311-1327. PubMed ID: 31654243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial.
    Frederich R; McNeill R; Berglind N; Fleming D; Chen R
    Diabetol Metab Syndr; 2012 Jul; 4(1):36. PubMed ID: 22828124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
    Dokken B
    J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.